Zurück
(1 Bewertungen)
dpa-AFX·Mehr Nachrichten von dpa-AFX
Original-Research: SYGNIS AG (von GBC AG): BUY
Original-Research: SYGNIS AG - von GBC AG
Einstufung von GBC AG zu SYGNIS AG
Unternehmen: SYGNIS AG ISIN: DE000A1RFM03
Anlass der Studie: Research Comment Empfehlung: BUY Kursziel: 4,05 EUR Kursziel auf Sicht von: End FY 2015 Letzte Ratingänderung: Analyst: Cosmin Filker, Felix Gode
Positive news flow about the direct marketing strategy; further distribution agreements closed and new product launched
After the successful placement of the capital increase in December 2014 (gross proceeds of issue: EUR4.95 million), SYGNIS AG implemented a series of measures for marketing its own product pipeline. As part of the new business strategy, which focuses on more intensive use of marketing potential, the company presented the first own product line in November 2014 with TruePrime. The technology which the company has developed itself and incorporated into TruePrime makes it possible to amplify the entire genome from tiny sample quantities of up to individual cells. In addition, TruePrime technology markedly reduces the occurrence of artefacts in DNA copying.
The first product in this product line was launched in January 2015 with the introduction of the TruePrime Single Cell WGA KIT. The plan is to use various distribution channels as part of worldwide direct marketing to intensively exploit the marketing potential.
Along with marketing via the newly introduced SYGNIS TruePrime online shop, the company will draw on a range of specialised distributors. It announced the signing of non-exclusive distribution agreements for this purpose. International partnerships have already been established with the German BioCat GmbH, the Spanish bioNova cientifica, s.l. the French OZYME France and the Canadian D-MARK BIOSCIENCES. Furthermore, the second-largest market for life science products is being addressed through the most recent distribution agreement with the Japanese company FUNAKOSHI Co. Ltd. These distribution agreements are particularly interesting because they cover all future products in the TruePrime family and therefore offer potentially high economies of scale. This has laid a foundation for the expected sales success of the TruePrime Single Cell WGA KIT at an early stage. We are anticipating further dynamic expansion of the distribution network.
In addition to this, introduction of the second product in the TruePrime product line was announced on 23/02/2015. The new product TruePrime WGA Kit amplifies DNA and the entire genome from various cell types and limited sample volumes whilst maintaining a similarly high quality. SYGNIS AG will also be using established distribution channels for these products.
In view of recent successes in expanding the distribution network and in product development, we think SYGNIS AG is making good progress in operational terms. As these assumptions remain unchanged, we will maintain our target price of EUR4.05 and reaffirm our BUY rating.
Die vollständige Analyse können Sie hier downloaden: www.more-ir.de/d/12745.pdf
Kontakt für Rückfragen Jörg Grunwald Vorstand GBC AG Halderstraße 27 86150 Augsburg 0821 / 241133 0 research@gbc-ag.de
übermittelt durch die EQS Group AG.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
ISIN DE000A1RFM03
dpa-AFX·Mehr Nachrichten von dpa-AFX
Original-Research: SYGNIS AG (von GBC AG): BUY
Original-Research: SYGNIS AG - von GBC AG
Einstufung von GBC AG zu SYGNIS AG
Unternehmen: SYGNIS AG ISIN: DE000A1RFM03
Anlass der Studie: Research Comment Empfehlung: BUY Kursziel: 4,05 EUR Kursziel auf Sicht von: End FY 2015 Letzte Ratingänderung: Analyst: Cosmin Filker, Felix Gode
Positive news flow about the direct marketing strategy; further distribution agreements closed and new product launched
After the successful placement of the capital increase in December 2014 (gross proceeds of issue: EUR4.95 million), SYGNIS AG implemented a series of measures for marketing its own product pipeline. As part of the new business strategy, which focuses on more intensive use of marketing potential, the company presented the first own product line in November 2014 with TruePrime. The technology which the company has developed itself and incorporated into TruePrime makes it possible to amplify the entire genome from tiny sample quantities of up to individual cells. In addition, TruePrime technology markedly reduces the occurrence of artefacts in DNA copying.
The first product in this product line was launched in January 2015 with the introduction of the TruePrime Single Cell WGA KIT. The plan is to use various distribution channels as part of worldwide direct marketing to intensively exploit the marketing potential.
Along with marketing via the newly introduced SYGNIS TruePrime online shop, the company will draw on a range of specialised distributors. It announced the signing of non-exclusive distribution agreements for this purpose. International partnerships have already been established with the German BioCat GmbH, the Spanish bioNova cientifica, s.l. the French OZYME France and the Canadian D-MARK BIOSCIENCES. Furthermore, the second-largest market for life science products is being addressed through the most recent distribution agreement with the Japanese company FUNAKOSHI Co. Ltd. These distribution agreements are particularly interesting because they cover all future products in the TruePrime family and therefore offer potentially high economies of scale. This has laid a foundation for the expected sales success of the TruePrime Single Cell WGA KIT at an early stage. We are anticipating further dynamic expansion of the distribution network.
In addition to this, introduction of the second product in the TruePrime product line was announced on 23/02/2015. The new product TruePrime WGA Kit amplifies DNA and the entire genome from various cell types and limited sample volumes whilst maintaining a similarly high quality. SYGNIS AG will also be using established distribution channels for these products.
In view of recent successes in expanding the distribution network and in product development, we think SYGNIS AG is making good progress in operational terms. As these assumptions remain unchanged, we will maintain our target price of EUR4.05 and reaffirm our BUY rating.
Die vollständige Analyse können Sie hier downloaden: www.more-ir.de/d/12745.pdf
Kontakt für Rückfragen Jörg Grunwald Vorstand GBC AG Halderstraße 27 86150 Augsburg 0821 / 241133 0 research@gbc-ag.de
übermittelt durch die EQS Group AG.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
ISIN DE000A1RFM03
